UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2016-11, Vol.375 (19), p.1856-1867

2016

Volltextzugriff (PDF)

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2016-11, Vol.375 (19), p.1856-1867

2016

Volltextzugriff (PDF)

SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets

Neoplasia (New York, N.Y.), 2021-05, Vol.23 (5), p.473-487

2021

Volltextzugriff (PDF)

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6505-6505

2020

Volltextzugriff (PDF)

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6000-6000

2019

Volltextzugriff (PDF)

Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget’s disease

Oncotarget, 2019-11, Vol.10 (62), p.6647-6650

2019

Volltextzugriff (PDF)

18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study

BMC cancer, 2018-05, Vol.18 (1), p.548-548, Article 548

2018

Volltextzugriff (PDF)

Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.6019-6019

2017

Volltextzugriff (PDF)

Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT099-CT099

2016

Volltextzugriff (PDF)

Medizinische Onkologie: Immuntherapie – nun auch für Kopf-Hals-Tumoren

Swiss medical forum, 2017-12, Vol.17 (5152)

2017

Volltextzugriff (PDF)

Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer

Radiation oncology (London, England), 2011-09, Vol.6 (1), p.120-120, Article 120

2011

Volltextzugriff (PDF)

Follow up after IMRT in oral cavity cancer: update

Radiation oncology (London, England), 2012-06, Vol.7 (1), p.84-84, Article 84

2012

Volltextzugriff (PDF)

Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study

Journal of oral and maxillofacial surgery, 2018-04, Vol.76 (4), p.775-784

2018

Volltextzugriff (PDF)

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Journal of clinical oncology, 2023-02, Vol.41 (4), p.790-802

2023

Volltextzugriff (PDF)

Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit

Molecular and Cellular Biology, 1998-03, Vol.18 (3), p.1379-1387

1998

Volltextzugriff (PDF)

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

Journal of clinical oncology, 2022-07, Vol.40 (21), p.2321-2332

2022

Volltextzugriff (PDF)

Oncologie médicale: Immunothérapie: désormais également pour les tumeurs de la tête et du cou

Forum médical suisse (En ligne), 2017-12, Vol.17 (5152)

2017

Volltextzugriff (PDF)

IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes

The Journal of clinical investigation, 2020-03, Vol.130 (3), p.1417-1430

2020

Volltextzugriff (PDF)

CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

The oncologist (Dayton, Ohio), 2018-09, Vol.23 (9), p.1079-1082

2018

Volltextzugriff (PDF)

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

The oncologist (Dayton, Ohio), 2022-03, Vol.27 (2), p.e194-e198

2022

Volltextzugriff (PDF)

Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel

Swiss dental journal, 2017-01, Vol.127 (6), p.520

2017

Volltextzugriff (PDF)

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

Oral oncology, 2022-05, Vol.128, p.105815-105815, Article 105815

2022

Volltextzugriff (PDF)

Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study

Radiotherapy and oncology, 2020-09, Vol.150, p.62-69

2020

Volltextzugriff (PDF)

IMRT/VMAT for malignancies in the head-and-neck region: Outcome in patients aged 80

Strahlentherapie und Onkologie, 2016-08, Vol.192 (8), p.526-536

2016

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(46)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(19)
Oncology
(15)
Female
(10)
Male
(10)
Adult
(8)
Treatment Outcome
(8)
Aged
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Aged, 80 And Over
(6)
Care And Treatment
(6)
Head And Neck Neoplasms - Drug Therapy
(6)
Middle Aged
(6)
Radiotherapy
(6)
Head And Neck Cancer
(5)
Prognosis
(5)
Squamous Cell Carcinoma Of Head And Neck - Drug Therapy
(5)
B7-H1 Antigen - Metabolism
(4)
Cetuximab - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget’s disease

18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study

Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy

Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

Medizinische Onkologie: Immuntherapie – nun auch für Kopf-Hals-Tumoren

Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer

Follow up after IMRT in oral cavity cancer: update

Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

Oncologie médicale: Immunothérapie: désormais également pour les tumeurs de la tête et du cou

IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes

CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study

IMRT/VMAT for malignancies in the head-and-neck region: Outcome in patients aged 80

Suchergebnisse filtern